BOSULIF 400 mg, film-coated tablet 28 tablets
Active ingredients: Bosutinib, Bosutinib monohydrate
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet28 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- BOSULIF 400 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- 2 plaquette(s) PVC (ACLAR RX) polytrifluorochloroéthylène PVC-Aluminium de 14 comprimé(s)
- Marketing authorisation holder
- PFIZER EUROPE MA EEIG (BELGIQUE)
- Reimbursement according to BDPM
- 100 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 7 Feb 2020
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Initial prescription by a hospital doctor
- Initial prescription by a specialist
- Renewal by a specialist only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
61669899CIP73014622CIP133400930146224Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| BOSUTINIBcomprimé | 400 mg · un comprimé | FT |
| BOSUTINIB MONOHYDRATÉcomprimé | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.